-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明，無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Head-To-Head Review: Quantum Genomics Société Anonyme (OTCMKTS:QNNTF) and Icosavax (NASDAQ:ICVX)
Head-To-Head Review: Quantum Genomics Société Anonyme (OTCMKTS:QNNTF) and Icosavax (NASDAQ:ICVX)
Icosavax (NASDAQ:ICVX – Get Rating) and Quantum Genomics Société Anonyme (OTCMKTS:QNNTF – Get Rating) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, profitability, dividends, risk and earnings.
Volatility and Risk
Icosavax has a beta of 1.33, suggesting that its stock price is 33% more volatile than the S&P 500. Comparatively, Quantum Genomics Société Anonyme has a beta of -0.35, suggesting that its stock price is 135% less volatile than the S&P 500.
Get Icosavax alerts:Insider and Institutional Ownership
82.4% of Icosavax shares are held by institutional investors. 39.1% of Icosavax shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Earnings & Valuation
This table compares Icosavax and Quantum Genomics Société Anonyme's top-line revenue, earnings per share and valuation.| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Icosavax | $7.80 million | 24.95 | -$66.97 million | ($2.93) | -1.67 |
| Quantum Genomics Société Anonyme | N/A | N/A | N/A | N/A | N/A |
Quantum Genomics Société Anonyme has lower revenue, but higher earnings than Icosavax.
Profitability
This table compares Icosavax and Quantum Genomics Société Anonyme's net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Icosavax | -1,326.23% | -36.82% | -35.11% |
| Quantum Genomics Société Anonyme | N/A | N/A | N/A |
Analyst Ratings
This is a breakdown of current ratings and target prices for Icosavax and Quantum Genomics Société Anonyme, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Icosavax | 0 | 0 | 2 | 0 | 3.00 |
| Quantum Genomics Société Anonyme | 0 | 0 | 0 | 0 | N/A |
Icosavax currently has a consensus price target of $34.00, suggesting a potential upside of 596.72%. Given Icosavax's higher probable upside, research analysts plainly believe Icosavax is more favorable than Quantum Genomics Société Anonyme.
Summary
Icosavax beats Quantum Genomics Société Anonyme on 6 of the 9 factors compared between the two stocks.
About Icosavax
(Get Rating)
Icosavax, Inc., a biopharmaceutical company, develops vaccines against infectious diseases. The company, with the help of its virus-like particle (VLP) platform technology, focuses primarily on life-threatening respiratory diseases. Its products in pipeline include IVX-121, a vaccine candidate with RSV target and is under Phase 1/1b clinical trial; IVX-A12, a respiratory syncytial virus (RSV) monovalent antigen candidate with RSV/human metapneumovirus (hMPV) bivalent target indication; IVX-241, a vaccine candidate with hMPV target; and IVX-411, an original receptor binding domain (RBD) sequence antigen with SARS-CoV-2 target indication and is under Phase 1/2 clinical trial. The company was incorporated in 2017 and is headquartered in Seattle, Washington.
About Quantum Genomics Société Anonyme
(Get Rating)
Quantum Genomics Société Anonyme, a biopharmaceutical company, develops drugs to treat cardiovascular diseases. It develops drugs based on brain aminopeptidase A inhibition (BAPAI) platform primarily to treat high blood pressure and heart failure. The company develops firibastat, a monotherapy drug that is in pivotal Phase III study for the treatment of hypertension, as well as in clinical trial for the treatment of heart failure. It is also developing QGC011 to treat hypertension with combination therapy; and QGC006 and QGC606 drug for the treatment of hypertension and heart failure. The company was incorporated in 2005 and is based in Paris, France.
Receive News & Ratings for Icosavax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Icosavax and related companies with MarketBeat.com's FREE daily email newsletter.
Icosavax (NASDAQ:ICVX – Get Rating) and Quantum Genomics Société Anonyme (OTCMKTS:QNNTF – Get Rating) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, profitability, dividends, risk and earnings.
納斯達克：ICVX-GET Rating(納斯達克代碼：ICVX-GET Rating)和量子基因社會́TÉ匿名(OTCMKTS：QNNTF-GET Rating)都是小盤醫療公司，但哪隻股票更好？我們將根據兩家公司的分析師建議、機構持股、估值、盈利能力、股息、風險和收益的強弱對它們進行比較。
Volatility and Risk
波動性和風險
Icosavax has a beta of 1.33, suggesting that its stock price is 33% more volatile than the S&P 500. Comparatively, Quantum Genomics Société Anonyme has a beta of -0.35, suggesting that its stock price is 135% less volatile than the S&P 500.
ICosavax的貝塔係數為1.33，這表明其股價的波動性比標準普爾500指數高33%。相比之下，量子基因組́té匿名者的貝塔係數為-0.35%，這表明其股價的波動性比標準普爾500指數低135%。
Insider and Institutional Ownership
內部人與機構持股
82.4% of Icosavax shares are held by institutional investors. 39.1% of Icosavax shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
ICosavax 82.4%的股份由機構投資者持有。ICosavax 39.1%的股份由內部人士持有。強大的機構持股表明，大型基金管理公司、捐贈基金和對衝基金相信，一家公司有望實現長期增長。
Earnings & Valuation
收益與估值
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Icosavax | $7.80 million | 24.95 | -$66.97 million | ($2.93) | -1.67 |
| Quantum Genomics Société Anonyme | N/A | N/A | N/A | N/A | N/A |
| 總收入 | 價格/銷售額比 | 淨收入 | 每股收益 | 市盈率 | |
| 伊科薩克斯 | 780萬美元 | 24.95 | -6,697萬元 | ($2.93) | -1.67 |
| 量子基因組學會́té匿名者 | 不適用 | 不適用 | 不適用 | 不適用 | 不適用 |
Quantum Genomics Société Anonyme has lower revenue, but higher earnings than Icosavax.
量子基因組社́té匿名者的收入低於Icoavax，但收益高於Icoavax。
Profitability
盈利能力
This table compares Icosavax and Quantum Genomics Société Anonyme's net margins, return on equity and return on assets.
此表比較了Icoavax和量子基因公司Société匿名者的淨利潤率、股本回報率和資產回報率。
| Net Margins | Return on Equity | Return on Assets | |
| Icosavax | -1,326.23% | -36.82% | -35.11% |
| Quantum Genomics Société Anonyme | N/A | N/A | N/A |
| 淨利潤率 | 股本回報率 | 資產回報率 | |
| 伊科薩克斯 | -1,326.23% | -36.82% | -35.11% |
| 量子基因組學會́té匿名者 | 不適用 | 不適用 | 不適用 |
Analyst Ratings
分析師評級
This is a breakdown of current ratings and target prices for Icosavax and Quantum Genomics Société Anonyme, as provided by MarketBeat.
這是由MarketBeat提供的Icoavax和量子基因組Société匿名者的當前評級和目標價格的細目。
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Icosavax | 0 | 0 | 2 | 0 | 3.00 |
| Quantum Genomics Société Anonyme | 0 | 0 | 0 | 0 | N/A |
| 銷售評級 | 保持評級 | 購買評級 | 強勁的買入評級 | 評級分數 | |
| 伊科薩克斯 | 0 | 0 | 2 | 0 | 3.00 |
| 量子基因組學會́té匿名者 | 0 | 0 | 0 | 0 | 不適用 |
Icosavax currently has a consensus price target of $34.00, suggesting a potential upside of 596.72%. Given Icosavax's higher probable upside, research analysts plainly believe Icosavax is more favorable than Quantum Genomics Société Anonyme.
Icoavax目前的普遍目標價為34美元，暗示潛在上行596.72%。鑑於Icoavax的上行可能性更高，研究分析師顯然認為Icoavax比量子基因組社會́té匿名者更有利。
Summary
摘要
Icosavax beats Quantum Genomics Société Anonyme on 6 of the 9 factors compared between the two stocks.
在兩隻股票比較的9個因素中，Icoavax在6個因素上擊敗了量子基因組公司SociétéAnanme。
About Icosavax
關於ICosavax
(Get Rating)
(獲取評級)
Icosavax, Inc., a biopharmaceutical company, develops vaccines against infectious diseases. The company, with the help of its virus-like particle (VLP) platform technology, focuses primarily on life-threatening respiratory diseases. Its products in pipeline include IVX-121, a vaccine candidate with RSV target and is under Phase 1/1b clinical trial; IVX-A12, a respiratory syncytial virus (RSV) monovalent antigen candidate with RSV/human metapneumovirus (hMPV) bivalent target indication; IVX-241, a vaccine candidate with hMPV target; and IVX-411, an original receptor binding domain (RBD) sequence antigen with SARS-CoV-2 target indication and is under Phase 1/2 clinical trial. The company was incorporated in 2017 and is headquartered in Seattle, Washington.
ICosavax，Inc.是一家生物製藥公司，開發針對傳染病的疫苗。該公司在其病毒樣顆粒(VLP)平臺技術的幫助下，主要專注於威脅生命的呼吸道疾病。該公司正在籌備的產品包括IVX-121，一種以RSV為靶標的候選疫苗，正處於1/1b期臨牀試驗；IVX-A12，一種具有RSV/人偏肺病毒(HMPV)二價靶標的呼吸道合胞病毒(RSV)單價抗原候選；IVX-241，一種以hMPV為靶標的疫苗候選；以及IVX-411，一種具有SARS-CoV-2靶標的原始受體結合結構域(RBD)序列抗原，正處於1/2期臨牀試驗。該公司成立於2017年，總部位於華盛頓州西雅圖。
About Quantum Genomics Société Anonyme
關於量子基因組學會́té匿名者
(Get Rating)
(獲取評級)
Quantum Genomics Société Anonyme, a biopharmaceutical company, develops drugs to treat cardiovascular diseases. It develops drugs based on brain aminopeptidase A inhibition (BAPAI) platform primarily to treat high blood pressure and heart failure. The company develops firibastat, a monotherapy drug that is in pivotal Phase III study for the treatment of hypertension, as well as in clinical trial for the treatment of heart failure. It is also developing QGC011 to treat hypertension with combination therapy; and QGC006 and QGC606 drug for the treatment of hypertension and heart failure. The company was incorporated in 2005 and is based in Paris, France.
量子基因組學會́té匿名者組織是一家生物製藥公司，開發治療心血管疾病的藥物。它開發基於腦氨基肽酶A抑制(BAPAI)平臺的藥物，主要用於治療高血壓和心力衰竭。該公司開發了一種單一療法藥物Friastat，目前正處於治療高血壓的關鍵第三階段研究，以及治療心力衰竭的臨牀試驗中。它還在開發以聯合療法治療高血壓的QGC011，以及治療高血壓和心力衰竭的QGC006和QGC606藥物。該公司成立於2005年，總部設在法國巴黎。
Receive News & Ratings for Icosavax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Icosavax and related companies with MarketBeat.com's FREE daily email newsletter.
接受ICosavax Daily的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對ICosavax和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧